8-((4-bromobenzyl)thio)-1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione | 1351935-96-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 8-((4-bromobenzyl)thio)-1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione
• 英文别名: 8-{[(4-bromophenyl)methyl]sulfanyl}caffeine；8-[(4-bromophenyl)methylsulfanyl]-1,3,7-trimethylpurine-2,6-dione
• CAS: 1351935-96-0
• 化学式: C₁₅H₁₅BrN₄O₂S
• 分子量: 395.28
• InChiKey: WVALAYLVPWLNQN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  83.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  8-((4-bromobenzyl)thio)-1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione 在 Oxone 作用下， 以 甲醇 、 水 为溶剂， 反应 5.0h， 以66.7%的产率得到8-(4-bromobenzylsulfonyl)-1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione
  参考文献：
  名称：

  [EN] MLKL INHIBITORS
  [FR] INHIBITEURS MLKL

  摘要：

  嘌呤衍生物，用于抑制细胞坏死性凋亡和/或人类MLKL；包含该衍生物的药物组合物；以及使用有效量的该化合物或组合物治疗MLKL介导的疾病的方法。所述MLKL介导的疾病是与坏死性凋亡相关的病理学，包括缺血再灌注损伤、神经退行性疾病、以及诸如急性胰腺炎、多发性硬化症、炎症性肠病和过敏性结肠炎等炎症性疾病。

  公开号：

  WO2018157800A1
• 作为产物：
  描述：

  8-氯-3,7-二氢-1,3,7-三甲基-1H-嘌呤-2,6-二酮 在 sodium hydrogen sulfide 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 生成 8-((4-bromobenzyl)thio)-1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione
  参考文献：
  名称：

  [EN] MLKL INHIBITORS
  [FR] INHIBITEURS MLKL

  摘要：

  嘌呤衍生物，用于抑制细胞坏死性凋亡和/或人类MLKL；包含该衍生物的药物组合物；以及使用有效量的该化合物或组合物治疗MLKL介导的疾病的方法。所述MLKL介导的疾病是与坏死性凋亡相关的病理学，包括缺血再灌注损伤、神经退行性疾病、以及诸如急性胰腺炎、多发性硬化症、炎症性肠病和过敏性结肠炎等炎症性疾病。

  公开号：

  WO2018157800A1

文献信息

• Thio- and aminocaffeine analogues as inhibitors of human monoamine oxidase
  作者：Hermanus P. Booysen、Christina Moraal、Gisella Terre’Blanche、Anél Petzer、Jacobus J. Bergh、Jacobus P. Petzer

  DOI：10.1016/j.bmc.2011.10.036

  日期：2011.12

  In a recent study it was shown that 8-benzyloxycaffeine analogues act as potent reversible inhibitors of human monoamine oxidase (MAO) A and B. Although the benzyloxy side chain appears to be particularly favorable for enhancing the MAO inhibition potency of caffeine, a variety of other C8 oxy substituents of caffeine also lead to potent MAO inhibition. In an attempt to discover additional C8 substituents of caffeine that lead to potent MAO inhibition and to explore the importance of the ether oxygen for the MAO inhibition properties of C8 oxy-substituted caffeines, a series of 8-sulfanyl-and 8-aminocaffeine analogues were synthesized and their human MAO-A and -B inhibition potencies were compared to those of the 8-oxycaffeines. The results document that the sulfanylcaffeine analogues are reversible competitive MAO-B inhibitors with potencies comparable to those of the oxycaffeines. The most potent inhibitor, 8-[(4-bromophenyl)methyl]sulfanyl}caffeine, exhibited an IC50 value of 0.167 mu M towards MAO-B. While the sulfanylcaffeine analogues also exhibit affinities for MAO-A, they display in general a high degree of MAO-B selectivity. The aminocaffeine analogues, in contrast, proved to be weak MAO inhibitors with a number of analogues exhibiting no binding to the MAO-A and -B isozymes. The results of this study are discussed with reference to possible binding orientations of selected caffeine analogues within the active site cavities of MAO-A and -B. MAO-B selective sulfanylcaffeine derived inhibitors may act as lead compounds for the design of antiparkinsonian therapies. (C) 2011 Elsevier Ltd. All rights reserved.
• [EN] MLKL INHIBITORS<br/>[FR] INHIBITEURS MLKL
  申请人：NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING

  公开号：WO2018157800A1

  公开（公告）日：2018-09-07

  Purine derivatives that inhibit cellular necroptosis and/or human MLKL, pharmaceutical compositions thereof, and methods of treating an MLKL-mediated disorder with an effective amount of the compound or composition. Said MLKL-mediated disorder is pathology associated necroptosis, including ischemia-reperfusion damage, neurodegeneration, and inflammatory diseases such as acute pancreatitis, multiple sclerosis, inflammatory bowel disease, and allergic colitis.

  嘌呤衍生物，用于抑制细胞坏死性凋亡和/或人类MLKL；包含该衍生物的药物组合物；以及使用有效量的该化合物或组合物治疗MLKL介导的疾病的方法。所述MLKL介导的疾病是与坏死性凋亡相关的病理学，包括缺血再灌注损伤、神经退行性疾病、以及诸如急性胰腺炎、多发性硬化症、炎症性肠病和过敏性结肠炎等炎症性疾病。